Patents Assigned to Regeneron Pharmaceuticals, Inc.
  • Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
    Patent number: 11834500
    Abstract: The present invention relates to antigen-binding molecules, including bispecific antigen-binding molecules that bind human GP130 and/or human leptin receptor (LEPR), and the use of such antigen-binding molecules for the treatment of conditions and disorders related to leptin deficiency or leptin resistance. The bispecific antigen-binding molecules of the present invention can be, e.g., bispecific antibodies comprising a first antigen-binding domain that specifically binds human GP130 and a second antigen-binding domain that specifically binds human LEPR. The bispecific antigen-binding molecules of the present invention are useful in therapeutic applications where induced leptin and/or LEPR-mediated signaling would be beneficial, e.g., in the treatment of obesity, lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 5, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos
  • INTERLEUKIN-2 PROPROTEINS AND USES THEREOF
    Publication number: 20230382969
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: May 26, 2023
    Publication date: November 30, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Supriya PATEL, Tong ZHANG, Jiaxi WU, Aaron CHANG, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • Medical imaging table, table support assembly, probe support assembly, system, and method of use
    Patent number: 11826196
    Abstract: A system including: a table assembly for supporting a subject in one or more examination positions; a table support assembly for supporting the table assembly, wherein the table support assembly includes: one or more moving mechanisms controlled to move the table assembly relative to a reference point along one or more axes, and to rotate the table assembly around the one or more axes; and a probe support assembly comprising: a grip for holding a probe; and an arrangement of a plurality of arms and joints controlled to movably support the probe that is held by the grip, wherein the probe support assembly is removably arranged at a predetermined position and orientation relative to the table support assembly to permit movement of the table support assembly and the probe support assembly for reproduction of a position and orientation of the probe relative to the subject supported by the table assembly.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: November 28, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Sam Cichon, Michael E. Dunn
  • Compositions and methods for treating cancer
    Patent number: 11826386
    Abstract: Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: November 28, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David DiLillo, Thomas Craig Meagher
  • loss of function rodent model
    Patent number: 11825819
    Abstract: This disclosure relates to a genetically modified rodent and use thereof as a rodent model. More specifically, this disclosure relates to rodent (e.g., mouse or rat) comprising a loss of function mutation in an endogenous Crnn (cornulin) gene, and to use of such a rodent animal as a rodent model of skin inflammation disorders (e.g., psoriasis).
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 28, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Claudia Gonzaga-Jauregui, Sokol Haxhinasto, Zaruhi Hovhannisyan, Kavita Praveen
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20230374108
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 29, 2023
    Publication date: November 23, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • Assembly line with integrated electronic visual inspection
    Patent number: 11823371
    Abstract: Methods and systems are disclosed for obtaining a first image of a tray, determining a presence or absence of one or more first patterns in the first image, determining a rotation of each the one or more first patterns in the first image, and performing an action based on the presence or absence and the rotation of the one or more first patterns in the first image.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: November 21, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jason Eugene Smith, Christopher S. Kanel, Patrick McDonough, Robert Sterling Nesbitt, Taylor MacEwen
  • Methods and compositions for the targeted modification of a genome
    Patent number: 11820997
    Abstract: Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the LTVEC with a CRISPR/Cas system. Compositions and methods for generating a genetically modified non-human animal comprising one or more targeted genetic modifications in their germline are also provided.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Wojtek Auerbach, Ka-Man Venus Lai, David M. Valenzuela, George D. Yancopoulos
  • Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
    Patent number: 11820982
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Goncalo Abecasis, Aris Baras
  • Anti-NPR1 antibodies and uses thereof
    Patent number: 11820826
    Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Michael E. Dunn, Jia Su, Jason Mastaitis, Jesper Gromada, Lori C. Morton
  • Human antibodies to human delta like ligand 4
    Patent number: 11820815
    Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
  • Cell culture medium for eukaryotic cells
    Patent number: 11821001
    Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Wei Xue, John Chen, Carolyn Scott, Theodore Loney, Nathaniel Golden
  • Anti-PTCRA antibody-drug conjugates and uses thereof
    Patent number: 11814428
    Abstract: The present disclosure provides antibody-drug conjugates comprising anti-PTCRA antibodies and methods of using the same. The ADCs of the disclosure are useful for the treatment of T-ALL and other disorders related to elevated expression of PTCRA.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 14, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Frank Kuhnert, Michael Van Meter, Thomas Nittoli
  • Citrate buffered VEGF antagonist formulations
    Patent number: 11806398
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • Method for generating high affinity antibodies
    Patent number: 11808766
    Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Robert Babb, James P. Fandl
  • Detection and quantification of glycosylated peptides
    Patent number: 11807665
    Abstract: A method of purification and/or separation of glycopeptides and quantitation of same. The method includes contacting a sample comprising glycopeptides to a hydrophilic enrichment substrate under conditions that permit the glycopeptides to bind to the hydrophilic enrichment substrate. The glycopeptides are eluted from the hydrophilic enrichment substrate with an ammonium formate and acetonitrile (ACN) in water solution to create an enriched glycopeptide sample, which may be subjected to analysis to identify specific glycopeptides.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Avraham Z. Rosenberg, Biao Shen
  • Support for test device
    Patent number: 11801513
    Abstract: A support holder for a test device is disclosed, wherein the holder may include a base having a first plurality of sidewalls having a first length and a second plurality of sidewalls having a second length, wherein the second length is greater than the first length, wherein the plurality of sidewalls define a cavity in the base, the cavity including a surface for receiving a portion of the test device; and a plurality of projections extending away from the base, wherein each projection of the plurality of projections is configured to be associated with a leg portion, and wherein a first sidewall of the first plurality of sidewalls includes a center notch positioned between a first corner portion and a second corner portion, and wherein a second sidewall of the first plurality of sidewalls includes a removable portion configured to cover an opening into an interior of the base.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: October 31, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Hunter, Steven Davis, Melissa Sher, David Vanhoute
  • NUCLEASE-MEDIATED REPEAT EXPANSION
    Publication number: 20230337645
    Abstract: Nuclease-mediated methods for expanding repeats already present at a genomic locus are provided. Non-human animal genomes, non-human animal cells, and non-human animals comprising a heterologous hexanucleotide repeat expansion sequence inserted at an endogenous C9orf72 locus and methods of making such non-human animal cells and non-human animals through nuclease-mediated repeat expansion are also provided. Methods of using the non-human animal cells or non-human animals to identify therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative disorders associated with repeat expansion at the C9orf72 locus are also provided.
    Type: Application
    Filed: May 12, 2023
    Publication date: October 26, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daisuke Kajimura, Aarti Sharma-Kanning, Brittany Dubose, Gustavo Droguett, Chia-Jen Siao, Junko Kuno, David Frendewey, Brian Zambrowicz
  • NOVEL ANTIGEN BINDING MOLECULE FORMATS
    Publication number: 20230340105
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Application
    Filed: May 17, 2023
    Publication date: October 26, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • COMPOSITIONS AND METHODS FOR REDUCING BIOBURDEN IN CHROMATOGRAPHY
    Publication number: 20230343086
    Abstract: The invention provides methods for microbial bioburden reduction of various chromatography matrices, including bioburden reduction in the context of large-scale Protein A-based affinity chromatography columns.
    Type: Application
    Filed: July 5, 2023
    Publication date: October 26, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nathan L. MAO, Wenbin Ql, Bernhard SCHILLING, Scott CARVER